Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (133) 133
male (100) 100
adult (99) 99
middle aged (96) 96
female (94) 94
hematology (83) 83
adolescent (60) 60
index medicus (44) 44
transplantation (44) 44
aged (37) 37
oncology (34) 34
transplantation, homologous (34) 34
treatment outcome (32) 32
bone-marrow-transplantation (31) 31
retrospective studies (29) 29
immunology (28) 28
disease-free survival (24) 24
prognosis (24) 24
survival analysis (24) 24
bone marrow transplantation (23) 23
remission induction (22) 22
leukemia (21) 21
recurrence (21) 21
acute disease (19) 19
colony-stimulating factor (19) 19
survival (19) 19
umcg approved (19) 19
young adult (19) 19
acute myelogenous leukemia (18) 18
elderly-patients (17) 17
risk factors (17) 17
survival rate (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (16) 16
bone marrow (15) 15
bone-marrow transplantation (15) 15
hematology, oncology and palliative medicine (15) 15
stem cell transplantation (15) 15
transplantation, autologous (15) 15
acute myeloid-leukemia (14) 14
follow-up studies (14) 14
child (13) 13
graft vs host disease - etiology (13) 13
hematopoietic stem cell transplantation (13) 13
incidence (13) 13
prospective studies (13) 13
therapy (13) 13
analysis (12) 12
bone marrow transplantation - adverse effects (12) 12
chemotherapy (12) 12
hematopoietic stem cell transplantation - adverse effects (12) 12
stem cells (12) 12
stem-cell transplantation (12) 12
graft vs host disease - immunology (11) 11
hematopoietic stem cell transplantation - methods (11) 11
leukemia - therapy (11) 11
t-lymphocytes - immunology (11) 11
blood (10) 10
chronic myelogenous leukemia (10) 10
cyclosporine (10) 10
histocompatibility testing (10) 10
leukemia, myeloid, acute - drug therapy (10) 10
lymphoma, non-hodgkin - therapy (10) 10
peripheral-blood (10) 10
remission (10) 10
trial (10) 10
adults (9) 9
age factors (9) 9
child, preschool (9) 9
chronic disease (9) 9
cytarabine - administration & dosage (9) 9
disease (9) 9
graft (9) 9
graft vs host disease - mortality (9) 9
graft vs host disease - prevention & control (9) 9
hematopoietic stem cell transplantation - mortality (9) 9
leukemia, myeloid, acute - mortality (9) 9
medicine, general & internal (9) 9
multiple myeloma - therapy (9) 9
non-hodgkins-lymphoma (9) 9
proportional hazards models (9) 9
rituximab (9) 9
1st remission (8) 8
abridged index medicus (8) 8
care and treatment (8) 8
combined modality therapy (8) 8
hematopoietic stem cells (8) 8
high-dose therapy (8) 8
leukemia, myeloid, acute - therapy (8) 8
mortality (8) 8
risk-factors (8) 8
unrelated donors (8) 8
versus-host-disease (8) 8
allogeneic stem cell transplantation (7) 7
antineoplastic agents - therapeutic use (7) 7
antineoplastic combined chemotherapy protocols - administration & dosage (7) 7
intensive chemotherapy (7) 7
lymphocytes (7) 7
prevention (7) 7
recipients (7) 7
relapse (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Forced overexpression of either of the two common human Foxp3 isoforms can iduce regulatory T cells from CD4+CD25- cells
by Aarts-Riemens, Tineke and Emmelot, Maarten E and Verdonck, Leo F and Mutis, Tuna
European Journal of Immunology, ISSN 0014-2980, 05/2008, Volume 38, Issue 5, pp. 1381 - 1390
The forkhead/winged helix transcription factor (Foxp3) is expressed as two different isoforms in humans: the full-length isoform (Foxp3FL) and an... 
Human | Retroviral transduction | Transcription factors | Foxp3 isoforms | Immunology | Regulatory T cells | Immunology and Allergy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis
by Salut Brunet and Myriam Labopin and Jordi Esteve and Jan Cornelissen and Gerard Socié and Anna P. Iori and Leo F. Verdonck and Liisa Volin and Alois Gratwohl and Jorge Sierra and Mohamad Mohty and Vanderson Rocha
Journal of Clinical Oncology, ISSN 0732-183X, 03/2012, Volume 30, Issue 7, pp. 735 - 741
textabstractPurpose: Patients with acute myeloid leukemia (AML) and FLT3/internal tandem duplication (FLT3/ITD) have poor prognosis if treated with... 
AML | SURVIVAL | MARROW | PROMYELOCYTIC LEUKEMIA | ONCOLOGY | PROGNOSIS | NORMAL CYTOGENETICS | PERIPHERAL-BLOOD | MUTATIONS | STEM-CELL TRANSPLANTATION | COMBINATION | Recurrence | Prognosis | Humans | Middle Aged | Male | Treatment Outcome | Tandem Repeat Sequences | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Disease-Free Survival | Leukemia, Myeloid, Acute - enzymology | Adolescent | Adult | Female | Leukemia, Myeloid, Acute - surgery | Retrospective Studies | Hematopoietic Stem Cell Transplantation - methods | Leukemia, Myeloid, Acute - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
by Löwenberg, Bob and Ossenkoppele, Gert J and van Putten, Wim and Schouten, Harry C and Graux, Carlos and Ferrant, Augustin and Sonneveld, Pieter and Maertens, Johan and Jongen-Lavrencic, Mojca and von Lilienfeld-Toal, Marie and Biemond, Bart J and Vellenga, Edo and Kooy, Marinus van Marwijk and Verdonck, Leo F and Beck, Joachim and Döhner, Hartmut and Gratwohl, Alois and Pabst, Thomas and Verhoef, Gregor and Swiss Grp Clinical Canc Res SAKK C and Dutch-Belgian Cooperative Trial Gr and German AML Study Grp AMLSG and Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and German AML Study Group (AMLSG) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group
The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 13, pp. 1235 - 1248
Patients with acute myeloid leukemia (AML) who were more than 60 years of age received treatment to induce a complete remission that consisted of cytarabine... 
TRIAL | MEDICINE, GENERAL & INTERNAL | COOPERATIVE-GROUP | COLONY-STIMULATING FACTOR | SOUTHWEST-ONCOLOGY-GROUP | REMISSION-INDUCTION CHEMOTHERAPY | RANDOMIZED PHASE-III | EUROPEAN ORGANIZATION | RISK MYELODYSPLASTIC SYNDROME | CYTARABINE | ELDERLY-PATIENTS | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Leukemia, Myelomonocytic, Acute - drug therapy | Stem Cell Transplantation | Antibodies, Monoclonal, Humanized | Leukemia, Myelomonocytic, Acute - therapy | Aminoglycosides - administration & dosage | Aged, 80 and over | Female | Remission Induction - methods | Daunorubicin - administration & dosage | Proportional Hazards Models | Combined Modality Therapy | Cytarabine - administration & dosage | Daunorubicin - adverse effects | Antibiotics, Antineoplastic - administration & dosage | Antibodies, Monoclonal - administration & dosage | Survival Analysis | Aged | Infusions, Intravenous | Leukemia, Myelomonocytic, Acute - mortality | Aged patients | Usage | Dosage and administration | Daunorubicin | Health aspects | Medical treatment | Leukemia | Age | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
by Monique Terwijn and Wim L.J. van Putten and Angèle Kelder and Vincent H.J. van der Velden and Rik A. Brooimans and Thomas Pabst and Johan Maertens and Nancy Boeckx and Georgine E. de Greef and Peter J.M. Valk and Frank W.M.B. Preijers and Peter C. Huijgens and Angelika M. Dräger and Urs Schanz and Mojca Jongen-Lavrecic and Bart J. Biemond and Jakob R. Passweg and Michel van Gelder and Pierre Wijermans and Carlos Graux and Mario Bargetzi and Marie-Cecile Legdeur and Jurgen Kuball and Okke de Weerdt and Yves Chalandon and Urs Hess and Leo F. Verdonck and Jan W. Gratama and Yvonne J.M. Oussoren and Willemijn J. Scholten and Jennita Slomp and Alexander N. Snel and Marie-Christiane Vekemans and Bob Löwenberg and Gert J. Ossenkoppele and Gerrit J. Schuurhuis
Journal of Clinical Oncology, ISSN 0732-183X, 11/2013, Volume 31, Issue 31, pp. 3889 - +
Purpose Half the patients with acute myeloid leukemia (AML) who achieve complete remission (CR), ultimately relapse. Residual treatment-surviving leukemia is... 
SURVIVAL | TRIAL | RELAPSE | DIAGNOSIS | THERAPY | ONCOLOGY | RISK | INDUCTION | EXPRESSION | CLINICAL-SIGNIFICANCE | REMISSION | Flow Cytometry - methods | Prognosis | Consolidation Chemotherapy - methods | Humans | Middle Aged | Induction Chemotherapy - methods | Proportional Hazards Models | Male | Neoplasm Recurrence, Local - diagnosis | Remission Induction | Young Adult | Leukemia, Myeloid, Acute - diagnosis | Neoplasm, Residual - diagnosis | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Granulocyte Colony-Stimulating Factor - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Cytarabine Dose for Acute Myeloid Leukemia
by Löwenberg, Bob and Pabst, Thomas and Vellenga, Edo and van Putten, Wim and Schouten, Harry C and Graux, Carlos and Ferrant, Augustin and Sonneveld, Pieter and Biemond, Bart J and Gratwohl, Alois and de Greef, Georgine E and Verdonck, Leo F and Schaafsma, Martijn R and Gregor, Michael and Theobald, Matthias and Schanz, Urs and Maertens, Johan and Ossenkoppele, Gert J and Swiss Grp Clinical Canc Res SAKK and Dutch-Belgian Cooperative Trial and Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group
The New England Journal of Medicine, ISSN 0028-4793, 03/2011, Volume 364, Issue 11, pp. 1027 - 1036
High-dose cytarabine is up to 30 times the standard dose of this drug. Although more effective, the higher dose is more toxic. In this study, an intermediate... 
CYTOSINE-ARABINOSIDE | MEDICINE, GENERAL & INTERNAL | COLONY-STIMULATING FACTOR | INDUCTION THERAPY | 1ST REMISSION | REPETITIVE CYCLES | ADULTS | POSTREMISSION CHEMOTHERAPY | GROUP-B | DAUNORUBICIN | INTENSIFICATION | Prognosis | Humans | Middle Aged | Proportional Hazards Models | Male | Combined Modality Therapy | Cytarabine - adverse effects | Remission Induction | Cytarabine - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Leukemia, Myeloid, Acute - mortality | Stem Cell Transplantation | Young Adult | Adolescent | Antimetabolites, Antineoplastic - adverse effects | Intention to Treat Analysis | Survival Analysis | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Leukemia, Myeloid, Acute - therapy | Dosage and administration | Cytarabine | Studies | Consolidation | Medical treatment | Age | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text High EVI1 Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities
by Stefan Gröschel and Sanne Lugthart and Richard F. Schlenk and Peter J.M. Valk and Karina Eiwen and Chantal Goudswaard and Wim J.L. van Putten and Sabine Kayser and Leo F. Verdonck and Michael Lübbert and Gert-Jan Ossenkoppele and Ulrich Germing and Ingo Schmidt-Wolf and Brigitte Schlegelberger and Jürgen Krauter and Arnold Ganser and Hartmut Döhner and Bob Löwenberg and Konstanze Döhner and Ruud Delwel
Journal of Clinical Oncology, ISSN 0732-183X, 04/2010, Volume 28, Issue 12, pp. 2101 - 2107
Purpose The purpose of this study was to investigate frequency and prognostic significance of high EVI1 expression in acute myeloid leukemia (AML). Patients... 
SURVIVAL | DE-NOVO AML | THERAPY | COLONY-STIMULATING FACTOR | ONCOLOGY | MODEL | MYELODYSPLASTIC SYNDROMES | Recurrence | Translocation, Genetic | Up-Regulation | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | Transplantation, Homologous | Stem Cell Transplantation | Young Adult | Proto-Oncogenes - genetics | Time Factors | Polymerase Chain Reaction | Adult | Female | Retrospective Studies | Cytogenetic Analysis | Odds Ratio | Leukemia, Myeloid, Acute - therapy | Monosomy | Genetic Predisposition to Disease | Risk Assessment | Leukemia, Myeloid, Acute - pathology | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Transcription Factors - genetics | DNA-Binding Proteins - genetics | Chromosomes, Human, Pair 7 | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Adolescent | Chromosomes, Human, Pair 11 | MDS1 and EVI1 Complex Locus Protein | Leukemia, Myeloid, Acute - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Comparative Analysis of the Value of Allogeneic Hematopoietic Stem-Cell Transplantation in Acute Myeloid Leukemia With Monosomal Karyotype Versus Other Cytogenetic Risk Categories
by Jan J. Cornelissen and Dimitri Breems and Wim L.J. van Putten and Alois A. Gratwohl and Jakob R. Passweg and Thomas Pabst and Johan Maertens and H. Berna Beverloo and Marinus van Marwijk Kooy and Pierre W. Wijermans and Bart J. Biemond and Edo Vellenga and Leo F. Verdonck and Gert J. Ossenkoppele and Bob Löwenberg
Journal of Clinical Oncology, ISSN 0732-183X, 06/2012, Volume 30, Issue 17, pp. 2140 - 2146
textabstractPurpose: To determine to what extent allogeneic hematopoietic stem-cell transplantation (alloHSCT) quantitatively reduces relapse in acute myeloid... 
TRIAL | ADULT PATIENTS | POSTREMISSION THERAPY | COLONY-STIMULATING FACTOR | ONCOLOGY | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOGENOUS LEUKEMIA | INDUCTION | ELDERLY-PATIENTS | CHEMOTHERAPY | REMISSION | Recurrence | Humans | Middle Aged | Proportional Hazards Models | Treatment Outcome | Remission Induction | Transplantation, Homologous | Disease-Free Survival | Karyotyping | Adolescent | Cytogenetics - methods | Adult | Hematopoietic Stem Cell Transplantation - methods | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Autologous peripheral blood stem cell transplantation for acute myeloid leukemia
by Vellenga, Edo and van Putten, Wim and Ossenkoppele, Gert J and Verdonck, Leo F and Theobald, Matthias and Cornelissen, Jan J and Huijgens, Peter C and Maertens, Johan and Gratwohl, Alois and Schaafsma, Ron and Schanz, Urs and Graux, Carlos and Schouten, Harry C and Ferrant, Augustin and Bargetzi, Mario and Fey, Martin F and Löwenberg, Bob and Ferrant, A and Delannoy, A and Maertens, J and Verhoef, G and Bosly, A and Graux, C and Breems, D. A and Zachee, P and Mineur, P and Jaeger, E and Theobald, M and Beck, J and Fischer, Th and Bargetzi, M and Wernli, M and Gratwohl, A and Fey, M. F and Pabst, T and Chapuis, B and Chalandon, Y and Herr, A and Wuillemin, W. A and Gregor, M and Jacky, E and Schanz, U and Leoncini-Francini, L and Marini, G and Piquet, D and Zimmerli-Schwab, B and Hess, U and Binder, D and Kroner, Th and Biemond, B. J and Dutch-Belgian Hematooncology Coope and Swiss Grp Clinical Canc Res Collab and Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research Collaborative Group (SAKK) and for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), and Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)
Blood, ISSN 0006-4971, 2011, Volume 118, Issue 23, pp. 6037 - 6042
We report the results of a prospective, randomized phase 3 trial evaluating autologous peripheral blood stem cell transplantation (ASCT) versus intensive... 
INTENSIVE CHEMOTHERAPY | POSTREMISSION THERAPY | COLONY-STIMULATING FACTOR | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOGENOUS LEUKEMIA | ADULTS | HIGH-DOSE CYTARABINE | MUTATIONS | DAUNORUBICIN | HEMATOLOGY | 1ST COMPLETE REMISSION | Prognosis | Prospective Studies | Busulfan - therapeutic use | Humans | Middle Aged | Etoposide - therapeutic use | Transplantation, Autologous | Treatment Outcome | Antineoplastic Agents - therapeutic use | Remission Induction | Cyclophosphamide - therapeutic use | Antineoplastic Agents, Alkylating - therapeutic use | Leukemia, Myeloid, Acute - mortality | Young Adult | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Combined Modality Therapy - methods | Hematopoietic Stem Cell Transplantation - methods | Antineoplastic Agents, Phytogenic - therapeutic use | Leukemia, Myeloid, Acute - therapy | Mitoxantrone - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group
by Stefan Gröschel and Richard F. Schlenk and Jan Engelmann and Veronika Rockova and Veronica Teleanu and Michael W.M. Kühn and Karina Eiwen and Claudia Erpelinck and Marije Havermans and Michael Lübbert and Ulrich Germing and Ingo G.H. Schmidt-Wolf and H. Berna Beverloo and Gerrit J. Schuurhuis and Gert J. Ossenkoppele and Brigitte Schlegelberger and Leo F. Verdonck and Edo Vellenga and Gregor Verhoef and Peter Vandenberghe and Thomas Pabst and Mario Bargetzi and Jürgen Krauter and Arnold Ganser and Peter J.M. Valk and Bob Löwenberg and Konstanze Döhner and Hartmut Döhner and Ruud Delwel
Journal of Clinical Oncology, ISSN 0732-183X, 01/2013, Volume 31, Issue 1, pp. 95 - 103
textabstractPurpose: To evaluate the prognostic value of ecotropic viral integration 1 gene (EVI1) overexpression in acute myeloid leukemia (AML) with MLL gene... 
MLL-AF9 | TRIAL | TRANSFORMATION | ADULT PATIENTS | GENE | ONCOLOGY | TRANSLOCATIONS | ABNORMALITIES | TET2 | MUTATIONS | 60 YEARS OLD | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Male | Young Adult | Chromosomes, Human, Pair 9 - genetics | Proto-Oncogenes - genetics | Karyotyping | Adult | Female | Histone-Lysine N-Methyltransferase | Survival Rate | Chromosomes, Human, Pair 11 - genetics | Transcription Factors - genetics | DNA-Binding Proteins - genetics | Remission Induction | Leukemia, Myeloid, Acute - mortality | Myeloid-Lymphoid Leukemia Protein - genetics | Gene Rearrangement | Adolescent | Chromosome Aberrations | Aged | Neoplasm Staging | MDS1 and EVI1 Complex Locus Protein | Leukemia, Myeloid, Acute - classification | Leukemia, Myeloid, Acute - genetics | Translocation, Genetic - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
by Cornelissen, Jan J and van Putten, Wim L. J and Verdonck, Leo F and Theobald, Matthias and Jacky, Emanuel and Daenen, Simon M. G and van Marwijk Kooy, Marinus and Wijermans, Pierre and Schouten, Harry and Huijgens, Peter C and van der Lelie, Hans and Fey, Martin and Ferrant, Augustin and Maertens, Johan and Gratwohl, Alois and Lowenberg, Bob
Blood, ISSN 0006-4971, 2007, Volume 109, Issue 9, pp. 3658 - 3666
The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome... 
INTENSIVE CHEMOTHERAPY | POSTREMISSION THERAPY | TOTAL-BODY | COLONY-STIMULATING FACTOR | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOGENOUS LEUKEMIA | UNRELATED DONORS | EUROPEAN GROUP | HEMATOLOGY | AML-10 TRIAL | ACUTE MYELOBLASTIC-LEUKEMIA | Recurrence | Meta-Analysis as Topic | Age Factors | Follow-Up Studies | Histocompatibility Testing | Humans | Middle Aged | Risk Factors | Male | Survival Rate | Living Donors | Hematopoietic Stem Cell Transplantation - mortality | Transplantation Conditioning - mortality | Transplantation, Homologous | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Adolescent | Adult | Female | Retrospective Studies | Leukemia, Myeloid, Acute - therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text No Direct Effect of NOD2/CARD15 Variants On Clinical Outcome After Non-Myeloablative Allogeneic Stem Cell Transplantation
by van der Straaten, Hanneke M and Paquay, Martine M and Tilanus, Marcel G.J and Verdonck, Leo F and Huisman, Cynthia
Blood, ISSN 0006-4971, 11/2009, Volume 114, Issue 22, pp. 4322 - 4322
Abstract Abstract 4322 Background Single nucleotide polymorphisms (SNPs) in the innate immunity receptor NOD2/CARD15 have been demonstrated to modulate the... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Increasing Incidence of Chronic Graft-versus-Host Disease inAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
by Arai, Sally and Arora, Mukta and Wang, Tao and Spellman, Stephen R and He, Wensheng and Couriel, Daniel R and Urbano-Ispizua, Alvaro and Cutler, Corey S and Bacigalupo, Andrea A and Battiwalla, Minoo and Flowers, Mary E and Juckett, Mark B and Lee, Stephanie J and Loren, Alison W and Klumpp, Thomas R and Prockup, Susan E and Ringdén, Olle T.H and Savani, Bipin N and Socié, Gérard and Schultz, Kirk R and Spitzer, Thomas and Teshima, Takanori and Bredeson, Christopher N and Jacobsohn, David A and Hayashi, Robert J and Drobyski, William R and Frangoul, Haydar A and Akpek, Görgün and Ho, Vincent T and Lewis, Victor A and Gale, Robert Peter and Koreth, John and Chao, Nelson J and Aljurf, Mahmoud D and Cooper, Brenda W and Laughlin, Mary J and Hsu, Jack W and Hematti, Peiman and Verdonck, Leo F and Solh, Melhelm M and Norkin, Maxim and Reddy, Vijay and Martino, Rodrigo and Gadalla, Shahinaz and Goldberg, Jenna D and McCarthy, Philip L and Pérez-Simón, José A and Khera, Nandita and Lewis, Ian D and Atsuta, Yoshiko and Olsson, Richard F and Saber, Wael and Waller, Edmund K and Blaise, Didier and Pidala, Joseph A and Martin, Paul J and Satwani, Prakash and Bornhäuser, Martin and Inamoto, Yoshihiro and Weisdorf, Daniel J and Horowitz, Mary M and Pavletic, Steven Z
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 02/2015, Volume 21, Issue 2, pp. 266 - 274
Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host... 
Allogeneic transplant | Nonrelapse mortality | CGVHD | Incidence
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
by Arai, Sally and Arora, Mukta and Wang, Tao and Spellman, Stephen R and He, Wensheng and Couriel, Daniel R and Urbano-Ispizua, Alvaro and Cutler, Corey S and Bacigalupo, Andrea A and Battiwalla, Minoo and Flowers, Mary E and Juckett, Mark B and Lee, Stephanie J and Loren, Alison W and Klumpp, Thomas R and Prockup, Susan E and Ringdén, Olle T.H and Savani, Bipin N and Socié, Gérard and Schultz, Kirk R and Spitzer, Thomas and Teshima, Takanori and Bredeson, Christopher N and Jacobsohn, David A and Hayashi, Robert J and Drobyski, William R and Frangoul, Haydar A and Akpek, Görgün and Ho, Vincent T and Lewis, Victor A and Gale, Robert Peter and Koreth, John and Chao, Nelson J and Aljurf, Mahmoud D and Cooper, Brenda W and Laughlin, Mary J and Hsu, Jack W and Hematti, Peiman and Verdonck, Leo F and Solh, Melhelm M and Norkin, Maxim and Reddy, Vijay and Martino, Rodrigo and Gadalla, Shahinaz and Goldberg, Jenna D and McCarthy, Philip L and Pérez-Simón, José A and Khera, Nandita and Lewis, Ian D and Atsuta, Yoshiko and Olsson, Richard F and Saber, Wael and Waller, Edmund K and Blaise, Didier and Pidala, Joseph A and Martin, Paul J and Satwani, Prakash and Bornhäuser, Martin and Inamoto, Yoshihiro and Weisdorf, Daniel J and Horowitz, Mary M and Pavletic, Steven Z and Graft-Vs-Host Dis Working Comm CIB and Graft-vs-Host Disease Working Committee of the CIBMTR and Medicinska och farmaceutiska vetenskapsområdet and Uppsala universitet and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Centrum för klinisk forskning i Sörmland (CKFD)
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 2, pp. 266 - 274
Abstract Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic... 
Hematology, Oncology and Palliative Medicine | cGVHD | Allogeneic transplant | Nonrelapse mortality | Incidence | HEMATOPOIETIC-CELL TRANSPLANTATION | BONE-MARROW | UNRELATED DONORS | COMPETING RISKS | SINGLE-CENTER | IMMUNOLOGY | CONSENSUS DEVELOPMENT PROJECT | TRANSPLANTATION | REDUCED-INTENSITY | WORKING GROUP-REPORT | CLINICAL-TRIALS | STEM-CELL | HEMATOLOGY | Myeloablative Agonists - therapeutic use | Humans | Middle Aged | Child, Preschool | Infant | Male | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Transplantation, Homologous | Myelodysplastic Syndromes - therapy | Graft vs Host Disease - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Odds Ratio | Child | Graft vs Host Disease - etiology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Infant, Newborn | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - pathology | International Cooperation | Graft vs Host Disease - pathology | Leukemia, Myeloid, Acute - mortality | Adolescent | Myelodysplastic Syndromes - mortality | Survival Analysis | Bone Marrow Transplantation - adverse effects | Myelodysplastic Syndromes - pathology | Chronic Disease | Medicine, Experimental | Bone marrow | Medical research | Reports | Transplantation | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Immunosuppressive therapy for hypoplastic myelodysplastic syndrome
by Biesma, Douwe H and van den Tweel, Jan G and Verdonck, Leo F
Cancer, ISSN 0008-543X, 04/1997, Volume 79, Issue 8, pp. 1548 - 1551
BACKGROUND Hypoplastic myelodysplastic syndrome (MDS) is characterized by dysplasia and hypocellularity. The treatment of choice for young patients is bone... 
Blood/Bone Marrow | dysplasia | cyclosporin‐A | antithymocyte globulin | immunosuppressants | pancytopenia | hypoplastic myelodysplastic syndrome | hypocellularity | cyclospori n-A
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse
by Dimitri A. Breems and Wim L.J. Van Putten and Peter C. Huijgens and Gert J. Ossenkoppele and Gregor E.G. Verhoef and Leo F. Verdonck and Edo Vellenga and Georgine E. De Greef and Emanuel Jacky and Johannes Van der Lelie and Marc A. Boogaerts and Bob Löwenberg
Journal of Clinical Oncology, ISSN 0732-183X, 03/2005, Volume 23, Issue 9, pp. 1969 - 1978
Purpose The treatment of acute myeloid leukemia (AML) in first relapse is associated with unsatisfactory rates of complete responses that usually are short... 
CYTOGENETIC ABNORMALITIES | SURVIVAL | CYTOSINE-ARABINOSIDE | 2ND COMPLETE REMISSION | AML 10 TRIAL | COLONY-STIMULATING FACTOR | ACUTE MYELOGENOUS LEUKEMIA | SALVAGE THERAPY | UMCG Approved | CHEMOTHERAPY | DURATION | ONCOLOGY | Recurrence | Acute Disease | Prognosis | Humans | Leukemia, Myeloid - genetics | Middle Aged | Proportional Hazards Models | Antineoplastic Agents - therapeutic use | Adolescent | Survival Analysis | Adult | Leukemia, Myeloid - mortality | Leukemia, Myeloid - therapy | Salvage Therapy - methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Immunosuppressive therapy for hypoplastic myelodysplastic syndrome
by Biesma, DH and vandenTweel, JG and Verdonck, LF
CANCER, ISSN 0008-543X, 04/1997, Volume 79, Issue 8, pp. 1548 - 1551
BACKGROUND. Hypoplastic myelodysplastic syndrome (MDS) is characterized by dysplasia and hypocellularity. The treatment of choice for young patients is bone... 
dysplasia | PROPOSALS | antithymocyte globulin | ONCOLOGY | immunosuppressants | cyclosporin-A | pancytopenia | ANEMIA | hypoplastic myelodysplastic syndrome | MDS | hypocellularity | FEATURES | Cyclosporine - therapeutic use | Myelodysplastic Syndromes - therapy | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Antilymphocyte Serum - therapeutic use | Female | Male | Myelodysplastic Syndromes - blood | Prednisone - therapeutic use | Health aspects | Immunosuppressive agents | Myelodysplastic syndromes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Prognostic Impact of Germinal Center–Associated Proteins and Chromosomal Breakpoints in Poor-Risk Diffuse Large B-Cell Lymphoma
by Gustaaf W. van Imhoff and Evert-Jan G. Boerma and Bronno van der Holt and Ed Schuuring and Leo F. Verdonck and Hanneke C. Kluin-Nelemans and Philip M. Kluin
Journal of Clinical Oncology, ISSN 0732-183X, 09/2006, Volume 24, Issue 25, pp. 4135 - 4142
Purpose Outcome of diffuse large B-cell lymphoma (DLBCL) with a germinal center B-cell (GCB) expression profile is superior to that of non-GCB DLBCL. This... 
IMMUNOHISTOCHEMICAL EXPRESSION | GENE | RITUXIMAB | NON-HODGKINS-LYMPHOMA | CHOP | TISSUE MICROARRAY | ELDERLY-PATIENTS